Rabbit Polyclonal PSMB9 Antibody

+ +

•  

   
     All lanes : Anti-PSMB9 Antibody (C-term) at  1:2000 dilution Lane 1: A431 whole cell lysates Lane 2: mouse liver lysates Lane 3: Raji whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 23 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Overlay histogram showing Hela cells stained with P33024 (green line).  The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP12735b,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit lgG (H+L) (1583138) at 1/400 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P33024 staining PSMB9 in human spleen  sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The PSMB9 antibody targets the proteasome subunit beta type-9 (PSMB9), also known as low molecular mass protein 2 (LMP2) or β1i, a critical component of the immunoproteasome. This inducible proteasome variant is primarily expressed in immune cells and is upregulated by interferon-gamma (IFN-γ) during inflammatory responses. Unlike constitutive proteasomes, immunoproteasomes, including PSMB9. optimize the generation of antigenic peptides for major histocompatibility complex class I (MHC-I) presentation, enabling T-cell recognition of infected or cancerous cells. PSMB9 plays a key role in shaping immune responses by influencing peptide diversity and antigen processing efficiency.

PSMB9 antibodies are widely used in research to study immunoproteasome dynamics in autoimmune diseases (e.g., rheumatoid arthritis, lupus), viral infections, and cancer. They help detect PSMB9 expression in tissues or cells, assess immunoproteasome activity, and investigate dysregulation in pathological conditions. Studies also link PSMB9 polymorphisms to disease susceptibility, including type 1 diabetes and Crohn's disease, highlighting its clinical relevance. Additionally, PSMB9 antibodies aid in exploring therapeutic strategies targeting immunoproteasome inhibition to modulate immune activation. Their applications span techniques like Western blotting, immunohistochemistry, and flow cytometry, providing insights into adaptive immunity mechanisms and potential biomarkers for immune-related disorders.